Cancer Vaccine Prepared with Patient's Blood

Early clinical studies have confirmed the antitumor activity in breast, lung, and other primary malignant cancers of a new personalized vaccination that contains blood from the patient. Provisional US patents have been granted covering the steps of the vaccination procedure.

In brief, the vaccination comprises high production and release of tumor antigens inside the patient, followed by injection of tumor antigens obtained from the patient's own blood. First, the patient's blood is pretreated in order to reach high blood levels of tumor-released specific molecules and antigens. Following procedures to improve the blood's antigenicity, the antigen-containing blood is injected back into the patient, promoting an empowered immune response.

The developer states that the vaccination involves two innovations. Pretreating patients to make their tumors more antigenic, which is a new approach to elicit an immune response to tumors; and using blood as the source of vaccines, which allows repeating the vaccination all the time the tumor persists. The procedure was developed by PharmaBlood (North Miami Beach, FL, USA). The research team was led by a Uruguayan investigator, Dr. Eduardo Lasalvia, known for previous research in cancer immunology performed in France and now working for PharmaBlood.

PharmaBlood cautions that future clinical trials will be required to establish the strategic association and comparative efficiency of the new vaccine with previously available cancer treatments.




Related Links:
PharmaBlood